We are live on ! Find out more
BLRX icon

BioLineRX

12 hedge funds and large institutions have $28K invested in BioLineRX in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

2.12% less ownership

Funds ownership: 2.38% → 0.27% (-2.1%)

61% less funds holding

Funds holding: 31 → 12 (-19)

82% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 22

95% less capital inflows, than outflows

Capital inflows: $17.5K | Capital outflows: $376K

Holders
12
Holders Change
-19
Holders Change %
-61.29%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
3
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLRX Hedge Fund Activity: Q1 2025 in Review

12 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2025, worth a combined $28K — down 94% from $436K a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BLRX and 4 opened new positions — a net loss of 18 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Wells Fargo, adding an estimated $11.5K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $215K sold.

  • 12 institutional investors held BioLineRX (BLRX) as of Q1 2025, down from 31 in Q4 2024.
  • Funds reported $28K of BioLineRX stock for Q1 2025, down 94% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q1 2025 and 22 closed out, a net change of -18 holders.
  • The largest BioLineRX buyer in Q1 2025 was Wells Fargo, an estimated $11.5K added.
  • The largest BioLineRX seller in Q1 2025 was Highbridge Capital Management, an estimated $215K sold.

Based on aggregated 13F filings for Q1 2025.